clinical trial · NCT01625000
Safety and Efficacy of MP-214 in Patients With Schizophrenia
SchizophreniaMP-214 3mgMP-214 6mgMP-214 9mgRisperidone 4mgPlacebo
brief summary
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
started
May 1, 2012
primary completion
Aug 1, 2015
completion
Oct 1, 2015
last updated
Jan 5, 2026
official title
A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol